Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations

BACKGROUND: Patients with stage IV lung adenocarcinoma and EGFR mutation derive clinical benefit from treatment with EGFR tyrosine kinase inhibitors (TKI). Whether treatment with TKI improves outcomes in patients with resected lung adenocarcinoma and EGFR mutation is unknown. METHODS: Data were anal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Janjigian, Yelena Y., Park, Bernard J., Zakowski, Maureen F., Ladanyi, Marc, Pao, William, D’Angelo, Sandra P., Kris, Mark G., Shen, Ronglai, Zheng, Junting, Azzoli, Christopher G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3778680/
https://ncbi.nlm.nih.gov/pubmed/21150674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e318202bffe
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados